We can come pretty close. Assuming that $160M of the $207M of TEVA’s worldwide Treanda/Bendeka sales came from the US market and that Bendeka had a 75% share of the US Treanda/Bendeka market during the quarter, 2Q16 Bendeka sales were about $120M. EGRX’s 20% royalty on $120M of sales is $24M.
We’ll have the exact numbers when EGRX reports 2Q16 results next week.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.